What You Need to Know About Audit Prep
Introduction Audit readiness is no longer a reactive exercise reserved for the final stages of a clinical program. For early-phase trials, regulatory inspections and sponsor audits can occur at any point in the study lifecycle. As data integrity requirements continue to tighten and digital systems become more complex, audit preparation must be embedded into daily […]
How Stratification Is Changing Trial Populations in Phase I
Introduction Phase I clinical trials have traditionally focused on enrolling healthy volunteers under tightly controlled inclusion and exclusion criteria. While this model has supported early safety and pharmacokinetic evaluation, it is increasingly insufficient for today’s targeted, biomarker-driven therapies. As drug development shifts toward precision medicine, stratification is becoming a core design element even at the […]
Biologics vs. Biosimilars: What Makes Their Clinical Evaluation Different?
Introduction Biologic medicines now represent one of the fastest growing segments of the global pharmaceutical market. Monoclonal antibodies, recombinant proteins, cell based therapies, and other large molecule products are transforming how diseases such as cancer, autoimmune disorders, and rare genetic conditions are treated. As patents expire on many of these therapies, biosimilars are entering development […]
A Databases Advancing Healthy Volunteer Through Inclusive Recruitment Practices
Healthy volunteer databases are foundational to early-phase clinical research, yet many remain outdated and demographically narrow. Historically, registries have drawn from limited populations, producing data that fails to reflect real-world diversity. This lack of representation undermines scientific validity and creates downstream challenges for sponsors and regulators alike. The Regulatory and Scientific Case for Diversity Inclusive […]
What CROs Overlook When Recruiting for Long In-House Stays
Recruitment for clinical trials is never simple, but when studies require participants to remain in a clinic or research facility for extended periods, the challenges multiply. Long in-house stays, common in early-phase pharmacology trials, demand more than a standard recruitment plan. They require a retention strategy that begins before the first participant arrives and continues […]
Strategies for Ongoing Engagement from Subjects During Clinical Trials
Recruitment is only the first hurdle in a successful clinical trial. Maintaining participant engagement and ensuring compliance throughout the study are equally critical. High dropout rates or protocol deviations can jeopardize data integrity, delay timelines, and increase costs. For early phase CROs, proactive strategies to keep subjects involved and compliant can make the difference between […]
What Makes a CRO Audit-Ready All Year Long?
The phrase “Regulatory audit” can cause anxiety into even the most seasoned CRO professionals. For many, who see an audit as an isolated event, it conjures images of frantic, last-minute preparations, often referred to as “fire-drill audit culture.” This reactive approach, while sometimes seemingly effective in the short term, is unsustainable and carries risks. Patient […]
What Sponsors Need to Know Before Their First-in-Human Trial
Launching a first-in-human (FIH) study marks one of the most critical milestones in a drug’s journey from discovery to development. It is the moment when preclinical promise meets clinical reality, and every decision made at this stage, scientific, operational, and regulatory, can shape the trajectory of the entire program. For sponsors embarking on their first […]
Connecting Policy to CRO-Level Decisions in Bioequivalence Study Planning
Bioequivalence (BE) studies rely on a close connection between regulatory policy and the operational decisions made by CROs long before the first volunteer arrives on site. The success of a BE program depends on how well a CRO can interpret evolving guidance and translate it into protocol design, analytical preparation, statistical planning, recruitment strategies, and […]
How AI and Digital Monitoring Are Changing Clinical Trial Design in 2025
AI and digital monitoring have reached a turning point in 2025. After several years of incremental adoption, these tools are now reshaping how protocols are designed, how data is collected, and how sponsors think about feasibility and operational risk. The shift is not about replacing clinical teams. Instead, it is about elevating quality, accelerating insights, […]